| Literature DB >> 28993763 |
Ming Pan1, Congcong Lyu1, Junlong Zhao1,2,3, Bang Shen1,2.
Abstract
Toxoplasma gondii is a ubiquitous zoonotic pathogen belonging to apicomplexan parasites. Infection in humans and animals may cause abortion and other severe symptoms under certain circumstances, leading to great economical losses and public health problems. T. gondii was first discovered in China in 1955 and the corresponding work was published in 1957. Since then, a lot of work has been done on this parasite and the diseases it causes. This review summarizes the major progress made by Chinese scientists over the last 60 years, and gives our perspectives on what should be done in the near future. A wide variety of diagnostic approaches were designed, including the ones to detect T. gondii specific antibodies in host sera, and T. gondii specific antigens or DNA in tissue and environmental samples. Further work will be needed to translate some of the laboratory assays into reliable products for clinic uses. Epidemiological studies were extensively done in China and the sero-prevalence in humans increased over the years, but is still below the world average, likely due to the unique eating and cooking habits. Infection rates were shown to be fairly high in meat producing animals such as, pigs, sheep, and chickens, as well as in the definitive host cats. Numerous subunit vaccines in the form of recombinant proteins or DNA vaccines were developed, but none of them is satisfactory in the current form. Live attenuated parasites using genetically modified strains may be a better option for vaccine design. The strains isolated from China are dominated by the ToxoDB #9 genotype, but it likely contains multiple subtypes since different ToxoDB #9 strains exhibited phenotypic differences. Further studies are needed to understand the general biology, as well as the unique features of strains prevalent in China.Entities:
Keywords: China; Toxoplasma gondii; epidemiology; genotype; vaccine
Year: 2017 PMID: 28993763 PMCID: PMC5622193 DOI: 10.3389/fmicb.2017.01825
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Number of papers published by scientists in China each year since 1957. The key word “Toxoplasma” and affiliation “China” were used to search the PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/) for papers published by scientists in China in international journals. The keywords “Toxoplasma” or “toxoplasmosis” or the Chinese equivalent of the two were used to search the Chinese library CNKI (http://www.cnki.net/) to estimate the papers in Chinese journals. Subsequently the numbers of papers from the two searches were reported by year.
Diagnostic methods developed by scientists in China.
| 93.9% (31/33) positive concordance compared with Western blot (100%) (human) | Wu et al., | ||
| The lowest detectable limit was 1:320 dilution of positive serum (dog and cat) | Jiang W. et al., | ||
| After 8 days infection, | Jiang et al., | ||
| Chen et al., | |||
| The detectable limit was 1:5,500 dilution of positive serum (rabbit) | Wang et al., | ||
| Sensitivity and specificity of IgG were 100 and 96%, respectively, while sensitivity and specificity of IgM were 100 and 94%, respectively (human) | Jin et al., | ||
| Detected circulating antigens at the concentration of 31.2 ng/mL, and no cross-reaction with other protozoa (human and rabbit) | Chen R. et al., | ||
| Circulating antigens could be detected from day 2 to day 14 (or even longer) after parasite infection (pig, goat, and sheep) | Wang et al., | ||
| Superior sensitivity than the conventional PCR, can detected | Yang et al., | ||
| Showed higher sensitivity than RT-PCR with the detection limit of 1 tachyzoite in 1 g pork (pig) | Qu et al., | ||
| The sensitivity was as higher (1 fg DNA), compared to conventional PCR (100 fg) (pig, sheep, cattle, and dog) | Lin et al., |
Figure 2Results of representative serological studies to estimate the prevalence of T. gondii in humans and animals in China. Data collected from both Chinese and English publications after the year 2010 were analyzed and graphed on the map of China, which was divided into six regions for data presentation. Sero-prevalence range and average (in parentheses) for each animal in each region are shown. ND, Not determined.
Genotypes of T. gondii parasites prevalent in China.
| Cancer patients | Diseased tissues | ToxoDB #9 (8) | ToxoDB #9: 65% | Cong et al., |
| Serum samples | ToxoDB #9 (9) | Wang L. et al., | ||
| Pigs | Hilar lymph nodes | ToxoDB #10 (5 | ToxoDB #9: 83% | Zhou et al., |
| Retail meat | ToxoDB #9 (1) | Wang H. et al., | ||
| Blood, heart and brain | ToxoDB #9 (3) | Li Y. N. et al., | ||
| Cats | Brain, tongue, Heart, liver, Blood, feces | ToxoDB #9 (29) | ToxoDB #9: 74% | Qian et al., |
| Lung | ToxoDB #10 (2) | ToxoDB #9: 53% | Zhang et al., | |
| Qinghai vole Plateau pika Tibetan ground-tit | Brain | ToxoDB #10 (4) | Zhang X. X. et al., | |
| Rats and mice | Brain | ToxoDB#9 (7) | Yan et al., | |
| Wild birds | Breast, muscle | ToxoDB #10 (1) | ToxoDB #9: 44% | Huang et al., |
| Pet birds | Brain | ToxoDB #3 (1) | Cong et al., | |
| heart | ToxoDB#9 (1) | Chen et al., | ||
| House sparrows | Heart, brain, lung | ToxoDB #3 (1) | Cong et al., | |
| Domestic rabbit | Brain, spleen, liver | ToxoDB #2 (1) | Zhou et al., | |
| Bats | Lung, heart, liver, spleen, stomach, intestine or kidney | ToxoDB #10 (4) | Jiang et al., | |
| liver | ToxoDB#10 (3) | Qin et al., | ||
| Black goats | Liver, lung, lymph nodes | ToxoDB#10 (7) | Miao et al., | |
| Sika deer | Liver, lung, muscle | ToxoDB#9 (6) | Cong et al., | |
| Farmed minks | Brain | ToxoDB#9 (5) | Zheng et al., | |
T. gondii vaccine candidates designed by scientists in China.
| DNA and vector vaccines | SAG1 | Increased survival time to 20.38 ± 3.38 days vs. control (13.25 ± 1.16 days) | Chen et al., |
| SAG1, SAG2 linked to A2/B subunits of cholera toxin | 40% survival rate in immunized mice | Cong et al., | |
| SAG1, ROP2 with IL-12 as adjuvant | Increased survival time to 22 days vs. control (4–8 days) | Zhang et al., | |
| SAG1-ROP2-SAG2 co-deliveried with IL-12 | Increased survival rate | Cui et al., | |
| SAG1, GRA1, GRA2, GRA4 antigen segments | The survival rate of BALB/c and C57BL/6 mice were 100 and 40%, respectively | Liu et al., | |
| SAG2C, SAG2D, SAG2X | Reduction of cyst burden (77%) in the brain | Zhang M. et al., | |
| MIC3 (suicidal vector pSCA1) | Increased the survival time to 15 days vs. control mice (5 days) | Fang et al., | |
| MIC3 (recombinant pseudorabies virus rPRV) | The survival rates of BALB/c mice injected with rPRV-MIC3 alone was 50% | Nie et al., | |
| MIC3, SAG1 (baculovirus vaccine BV-MIC3+BV-SAG1) | 50% of the mice survived | Fang et al., | |
| MIC6 | Increased survival time to 13.3 ± 1.2 days vs. control mice (7 days) | Peng et al., | |
| MIC8 | Increased survival time to 10.3 ± 0.9 days vs. control mice (5 days) | Liu M. M. et al., | |
| MIC11 | Increased the survival time to 15 days vs. control mice (8–10 days) | Tao et al., | |
| MIC13 | Increased survival time to 21.3 ± 11.3 days vs. control mice (5–10 days) and reduced number of cysts in brain of mice (57.14%) | Yuan et al., | |
| ROP9 | Increased survival time to 12.9 ± 2.9 days vs. control mice (6 days) | Chen et al., | |
| ROP16 | Increased survival time to 21.6 ± 9.9 days vs. control mice (7 days) | Yuan et al., | |
| ROP18 | Increased survival time to 27.9 ± 15.1 days vs. control mice (7 days) | Yuan et al., | |
| ROM1 | Increased survival time to 12.5 ± 0.7 days vs. control mice (5 days) | Li et al., | |
| GRA6 with levamisole as adjuvant | 53.3% survival | Sun et al., | |
| eIF4A | Increased survival time to 23.0 ± 5.5 days compared to control mice (7 days) | Chen et al., | |
| MIC3, GRA1 | Increased survival time to 12–19 days (15.7 ± 1.88) vs. control group survived for 3–5 days (4.5 ± 0.38) | Gong et al., | |
| MIC3, ROP18 | Increased survival time to 14–19 days vs. control mice (7 days) | Qu et al., | |
| Aspartic protease 1 | Increased the survival time to 16 days vs. control (7 days) | Zhao et al., | |
| CDPK1 with a plasmid encoding IL-15 and IL-21 | Increased survival time to 19.2 ± 5.1 days vs. control (6 days) and reduced the number of brain cysts (72.7%) | Chen et al., | |
| NTPase-II (pDREP) | 71.4% reduction in brain cysts | Zheng et al., | |
| Recombinant protein vaccines | ROP5 | Increased survival time to 12.1 ± 3.4 days vs. control (6 days) | Zheng et al., |
| ROP17 | Lower liver and brain parasite burdens (59.17 and 49.08%, respectively) and increased survival time by 50% | Wang H. L. et al., | |
| ROP18, ROP38 encapsulated in poly (lactide-co-glycolide) | 81.3% reduction of tissue cysts | Xu et al., | |
| Live vaccines | Induced protective immunity in an ocular toxoplasmosis model | Lu et al., | |
| Induced Th1 immune response and prolonged survival of mice | Tang et al., |
Effects of herbal medicines or their active components on Toxoplasma gondii.
| Artemisinin | 0.4 μg/mL (5 days) 1.3 μg/mL (14 days) | Inhibit plaque formation | Ke et al., |
| Ginkgolic acids | 167.1 μg/ml | No visible parasites in HFF cells after 48 h of exposure to ginkgolic acids (isolated from the | Chen R. et al., |
| Inontus obliquus polysaccharide | 3 mg/10 g/d | Decreased testicular spermatogenic cell pathology damage caused by | Liu Y. et al., |
| Radix glycyrrhizae | 5 g/Kg | While combined with sulfachloropyrazine-sodium (SPZ), the survival rate of mice was up to 50% | Jiang W. et al., |
| Oxymatrine, matrine | 100 mg/Kg | Decreased the number of tachyzoite (45.2 and 53.8%) and increased survival rate of mice to 67% | Zhang X. et al., |